Vascular endothelial growth factor A and cardiovascular disease in rheumatoid arthritis patients

Tissue Antigens

Volumn 77, Issue 4, 2011, Pages 291-297

  Rodriguez Rodriguez L ^a,b   Garcia Bermudez M ^a   Gonzalez Juanatey C ^c   Vazquez Rodriguez, T R ^c   Miranda Filloy, J A ^c   Fernandez Gutierrez B ^b   Llorca, J ^d,e   Martin J ^a   Gonzalez Gay M A ^c,f  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL XERAL CALDE   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Atherosclerosis; Cardiovascular disease; Genetics; Rheumatoid arthritis; Rs1570360; Rs2010963; VEGFA

Indexed keywords

LEUKOCYTE ANTIGEN; VASCULOTROPIN A;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; FEMALE; GENOTYPE; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALLELES; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SPAIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952372070     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2010.01625.x     Document Type: Article

References (53)

1. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006: 6: 508-19.
2. Ribatti D, Levi-Schaffer F, Kovanen PT. Inflammatory angiogenesis in atherogenesis-a double-edged sword. Ann Med 2008: 40: 606-21.
3. Moreno PR, Purushothaman KR, Fuster V et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004: 110: 2032-38.
4. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. Hum Pathol 1995: 26: 450-6.
5. Khatri JJ, Johnson C, Magid R et al. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 2004: 109: 520-5.
6. Virmani R, Kolodgie FD, Burke AP et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005: 25: 2054-61.
7. Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005: 112: 1813-24.
8. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001: 7: 425-9.
9. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999: 13: 9-22.
10. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998: 273: 13313-6.
11. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995: 146: 1029-39.
12. de Boer OJ, van der Wal AC, Teeling P, Becker AE. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc Res 1999: 41: 443-9.
13. Marumo T, Schini-Kerth VB, Busse R. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999: 48: 1131-7.
14. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001: 276: 7614-20.
15. Zhao Q, Egashira K, Inoue S et al. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 2002: 105: 1110-5.
16. Huez I, Créancier L, Audigier S, Gensac MC, Prats AC, Prats H. Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol 1998: 18: 6178-90.
17. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999: 60: 1245-9.
18. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004: 46: 293-8.
19. Shahbazi M, Fryer AA, Pravica V et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002: 13: 260-4.
20. Awata T, Inoue K, Kurihara S et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002: 51: 1635-9.
21. Lambrechts D, Storkebaum E, Morimoto M et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003: 34: 383-94.
22. Rueda B, Lopez-Nevot MA, Lopez-Diaz MJ, Garcia-Porrua C, Martín J, Gonzalez-Gay MA. A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J Rheumatol 2005: 32: 1737-41.
23. Salvarani C, Boiardi L, Casali B et al. Vascular endothelial growth factor gene polymorphisms in Behcet's disease. J Rheumatol 2004: 31: 1785-9.
24. del Rincón I, Escalante A. Atherosclerotic cardiovascular disease in rheumatoid arthritis. Curr Rheumatol Rep 2003: 5: 278-86.
25. Gazi IF, Boumpas DT, Mikhailidis DP, Ganotakis ES. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 2007: 25: 102-11.
26. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005: 35: 8-17.
27. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007: 57: 125-32.
28. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003: 108: 2957-63.
29. Dessein PH, Joffe BI, Veller MG, Stevens BA et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005: 32: 435-42.
30. Sattar N, McInnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 2005: 17: 286-92.
31. Lee SS, Joo YS, Kim WU et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001: 19: 321-4.
32. Ballara S, Taylor PC, Reusch P et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001: 44: 2055-64.
33. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988: 31: 315-24.
34. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993: 22 (4 Suppl A): 6A-13A.
35. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003: 114: 647-52.
36. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Martin J, Llorca J. Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 2008: 38: 67-70.
37. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007: 57: 1074-80.
38. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987: 30: 1205-13.
39. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008: 66: 87-98.
40. Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003: 82: 407-13.
41. Rueda B, González-Gay MA, López-Nevot MA et al. Analysis of vascular endothelial growth factor (VEGF) functional variants in rheumatoid arthritis. Hum Immunol 2005: 66: 864-8.
42. Han SW, Kim GW, Seo JS et al. VEGF gene polymorphisms and susceptibility to rheumatoid arthritis. Rheumatology (Oxford) 2004: 43: 1173-7.
43. Afuwape AO, Kiriakidis S, Paleolog EM. The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis. Histol Histopathol 2002: 17: 961-72.
44. Hultén LM, Levin M. The role of hypoxia in atherosclerosis. Curr Opin Lipidol 2009: 20: 409-14.
45. Ng CT, Biniecka M, Kennedy A et al. Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis 2010: 69: 1389-95.
46. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998: 41: 1258-65.
47. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995: 95: 1798-807.
48. Szekanecz Z, Besenyei T, Paragh G, Koch AE. Angiogenesis in rheumatoid arthritis. Autoimmunity 2009: 42: 563-73.
49. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008: 41: 278-86.
50. Holm PW, Slart RHJA, Zeebregts CJ, Hillebrands JL, Tio RA. Atherosclerotic plaque development and instability: a dual role for VEGF. Ann Med 2009: 41: 257-64.
51. Lee LY, Patel SR, Hackett NR et al. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg 2000: 69: 14-23.
52. Tio RA, Tkebuchava T, Scheuermann TH et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum Gene Ther 1999: 10: 2953-60.
53. Choi JS, Kim KB, Han W et al. Efficacy of therapeutic angiogenesis by intramyocardial injection of pCK-VEGF165 in pigs. Ann Thorac Surg 2006: 82: 679-86.